---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Incidence"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Incidence. Topics: Incidence of psoriasis in a retrospective cohort, electronic health records 2014 to 2018; Incidence of psoriasis by age, sex, and race; Overall incidence and incidence trend, 1970 to 1999; Range of adult incidence across countries: systematic review; 3 further topics. 7 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/incidence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Moderate-to-severe plaque psoriasis

<a id="topic-2.2.1.2.1-1"></a>

### Incidence of psoriasis in a retrospective cohort, electronic health records 2014 to 2018

> “Retrospective cohort analysis of psoriasis patients identified with electronic health records between 2014 and 2018.”
> “Incidence rate in the overall population (n = 2,152,192) was 63.8 (95% confidence interval [CI] 61.8-65.8) per 100,000 person-years.”
> “Incidence appears to be stable within a recent 5-year period.”

Source: [Burshtein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33253841/)

<a id="topic-2.2.1.2.1-2"></a>

### Incidence of psoriasis by age, sex, and race

> “Incidence increased with age and peaked among individuals aged 70 to 79 years (92.3 [95% CI 85.1-100.0] per 100,000 person-years).”
> “Incidence was similar between men (62.8 [95% CI 59.8-65.9] per 100,000 person-years) and women (64.8 [95% CI 62.2-67.4] per 100,000 person-years).”
> “Standardized incidence rate for Whites (75.3 [95% CI 72.7-78.0] per 100,000 person-years) was greater than that for Hispanic/Latino patients (52.2 [95% CI 44.9-60.3] per 100,000 person-years; P < .001), patients of other race (54.3 [95% CI 46.5-62.9] per 100,000 person-years; P < .001), and Blacks (24.9 [95% CI 21.4-28.8] per 100,000 person-years; P < .001).”

Source: [Burshtein et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33253841/)

<a id="topic-2.2.1.2.1-3"></a>

### Overall incidence and incidence trend, 1970 to 1999

> “The overall age and sex adjusted annual incidence of psoriasis was 78.9 per 100,000 (95% confidence interval [CI]: 75.0, 82.9).”
> “Incidence of psoriasis increased significantly over time from 50.8 in 1970–74 to reach 100.5 per 100,000 in 1995–1999 time period (p=0.001).”
> “Overall age-adjusted incidence in males (85.5 per 100,000; 95% CI: 79.5, 91.6) was higher than in females (73.2 per 100,000; 95% CI: 68.0, 78.4; p=0.003).”

Source: [Icen et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3028518/)

<a id="topic-2.2.1.2.1-4"></a>

### Range of adult incidence across countries: systematic review

> “In adults, the incidence of psoriasis varied from 30.3 per 100 000 person years (95% confidence interval 26.6 to 34.1) in Taiwan to 321.0 per 100 000 person years in Italy.”
> “The 23 studies that reported on the incidence of psoriasis in the general population were conducted mainly in western and eastern Europe (16 studies), and North America (six studies).”

Source: [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-2.2.1.2.1-5"></a>

### Global and high-income North America incidence, Global Burden of Disease Study 2021

| Location | ASIR in 1990 (per 100,000) | ASIR in 2021 (per 100,000) | Cases in 2021 |
| --- | --- | --- | --- |
| Global | “57.0(55.3–58.8)” | “62.0(60.1–63.9)” | “5,099,418.3 (4,945,748.1–5,254,031)” |
| High-income North America | “96.5 (93.6–99.4)” | “103.5 (100.8–106.1)” | “422,371.3 (410,310.8–434,102.1)” |

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.2.1-6"></a>

### Global incident cases and trend, Global Burden of Disease Study 2021

> “In 2021, the global burden of psoriasis remained severe with a total incidence of 5.10 million cases (95% CI: 4.95~5.25 million), representing a 78.76% increase since 1990.”
> “It was projected to increase from about 5.10 million cases in 2021 to 8.25 million cases in 2036, an increase of about 61.74%, indicating that the number of people with psoriasis has increased by at least twofold in the last 15 years.”

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.2.1-7"></a>

### Age-standardized incidence trend, Global Burden of Disease Study 2019

> “From 1990 to 2019, the global ASR significantly increased for RA (AAPC = 0.21), albeit the ASRs significantly decreased for AD (AAPC = −0.15), asthma (AAPC = −0.41), MS (AAPC = −0.26), psoriasis (AAPC = −0.77), IBD (AAPC = −0.32).”
> “The ASR of psoriasis unanimously decreased among the 21 regions, with the highest decrement observed in North Africa and the Middle East (AAPC = −0.90).”

Source: [GBD 2019 IMID Collaborators (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10507198/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
